AlphaGrep UK’s Rhythm Pharmaceuticals RYTM Stock Holding History

AlphaGrep UK’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,509	Closed	-$269K	–	915
2025 Q4	$269K	Buy	+2,509	New	+$266K	0.09%	491

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

AlphaGrep UK's RYTM Position: Q1 2026 in Review

AlphaGrep UK sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 2,509 shares — an estimated $269K sold.

AlphaGrep UK first reported a position in RYTM in Q4 2025 and held it in 1 quarter. The position peaked at $269K in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

AlphaGrep UK reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
AlphaGrep UK sold 2,509 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $269K.
AlphaGrep UK first reported a position in Rhythm Pharmaceuticals in Q4 2025 and held it in 1 quarter.
AlphaGrep UK's Rhythm Pharmaceuticals position peaked at $269K in Q4 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on AlphaGrep UK's 13F filing for Q1 2026, filed 13 Aug 2026.